Inflammatory bowel disease (IBD), the collective term for a group of chronic conditions characterised by inflammation of the gastrointestinal tract (including Crohn’s disease and ulcerative colitis), affects an estimated 1.4 million individuals in the US, and its incidence is increasing worldwide. Current treatments generally manage the symptoms rather than provide a cure, highlighting the need to develop effective molecular therapies. In this new study, Nathan Bahary and colleagues use zebrafish to demonstrate that a deficiency in phosphatidylinositol (PI) signalling could be involved in the pathogenesis of IBD. Abnormalities in PI signalling have been linked with gastrointestinal disorders; however, the mechanisms remained unclear. Here, the authors show that PI-synthesis-deficient zebrafish display persistent ER stress and disrupted intestinal architecture, resulting in IBD-like pathologies. These effects can be mimicked by pharmacological induction of ER stress, whereas abrogation of ER stress using chemical chaperones rescues the disease phenotype. These findings link PI signalling defects with ER-stress-mediated gastrointestinal disease, revealing a mechanism that could be targeted in the development of curative therapies for IBD. Page 93
Phosphatidylinositol signalling defects implicated in IBD Open Access
- Split-screen
- Views Icon Views Open Menu
- Open the PDF for in another window
-
Article Versions Icon
Versions
- Version of Record 01 January 2014
- Share Icon Share
-
Tools Icon
Tools
Open Menu
- Search Site
Phosphatidylinositol signalling defects implicated in IBD. Dis Model Mech 1 January 2014; 7 (1): 1. doi:
Download citation file:
Advertisement
Cited by
Call for papers – In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery

We invite you to submit your latest research to our upcoming special issue: In Vitro Models of Human Disease to Inform Mechanism and Drug Discovery, coordinated by DMM Editor Vivian Li (The Francis Crick Institute, London, UK), alongside Guest Editors Austin Smith (University of Exeter, UK) and Joseph Wu (Stanford University School of Medicine, USA).The deadline for submitting articles is 6 October 2025.
The Company of Biologists Workshops

For the last 15 years, our publisher, The Company of Biologists, has provided an apt environment to inspire biology and support biologists through our Workshops series. Read about the evolution of the Workshop series and revisit JEB's experience with hosting the first Global South Workshop.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
Propose a new Workshop for 2027

We are currently seeking proposals for Workshops to be held in 2027. As one of the scientific organisers of a The Company of Biologists Workshop, your involvement will be focused on interdisciplinary, cutting-edge science and promoting new partnerships and collaborations. We focus on the logistics. Are you thinking about proposing a topic for one of our Workshops? Apply by Friday 30 May 2025.
Other journals from
The Company of Biologists